- Home
- LEGH vs CRMD Comparison
LEGH vs CRMD Comparison
Compare LEGH & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEGH
- CRMD
- Stock Information
- Founded
- LEGH 2005
- CRMD 2006
- Country
- LEGH United States
- CRMD United States
- Employees
- LEGH N/A
- CRMD N/A
- Industry
- LEGH Homebuilding
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- LEGH Consumer Discretionary
- CRMD Health Care
- Exchange
- LEGH Nasdaq
- CRMD Nasdaq
- Market Cap
- LEGH 601.1M
- CRMD 576.4M
- IPO Year
- LEGH 2018
- CRMD 2010
- Fundamental
- Price
- LEGH $24.49
- CRMD $11.87
- Analyst Decision
- LEGH Buy
- CRMD Strong Buy
- Analyst Count
- LEGH 2
- CRMD 6
- Target Price
- LEGH $29.00
- CRMD $15.67
- AVG Volume (30 Days)
- LEGH 74.7K
- CRMD 1.2M
- Earning Date
- LEGH 11-12-2024
- CRMD 10-30-2024
- Dividend Yield
- LEGH N/A
- CRMD N/A
- EPS Growth
- LEGH N/A
- CRMD N/A
- EPS
- LEGH 2.18
- CRMD N/A
- Revenue
- LEGH $163,718,000.00
- CRMD $12,262,234.00
- Revenue This Year
- LEGH N/A
- CRMD N/A
- Revenue Next Year
- LEGH $8.19
- CRMD $300.00
- P/E Ratio
- LEGH $11.21
- CRMD N/A
- Revenue Growth
- LEGH N/A
- CRMD 41184.20
- 52 Week Low
- LEGH $19.42
- CRMD $2.89
- 52 Week High
- LEGH $29.31
- CRMD $13.85
- Technical
- Relative Strength Index (RSI)
- LEGH 49.66
- CRMD 71.01
- Support Level
- LEGH $22.36
- CRMD $7.91
- Resistance Level
- LEGH $24.98
- CRMD $11.50
- Average True Range (ATR)
- LEGH 0.65
- CRMD 0.57
- MACD
- LEGH 0.08
- CRMD 0.43
- Stochastic Oscillator
- LEGH 64.24
- CRMD 93.02
About LEGH Legacy Housing Corporation (TX)
Legacy Housing Corp builds, sell, and finance manufactured homes and tiny houses that are distributed through a network of independent retailers and company-owned stores and also sold directly to manufactured home communities. The company also provides financing options to customers to facilitate the sale of homes.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets.